Thomson Reuters, a distinguished brokerage company, has placed a 52-week price target of $29.21 on Impax Laboratories, Inc. (NASDAQ:IPXL) shares after it surveyed top market analysts. Calculating estimated earnings after taking into consideration different elements, it is predicted to come at $1.62 for the next fiscal and $N/A for underway quarter.
Analysts take into account the price to earnings ratio to estimate the firm’s valuation. This ratio, which is also called as the P/E ratio evaluates the company on relative expense factor. The formula to calculate ratio is stock’s latest price/ per share earnings. The P/E ratio of Impax Laboratories, Inc. (NASDAQ:IPXL) stands at 48.62.
Analysts also work out Price/Earnings Growth ratio in an attempt to estimate the valuation of a firm. This ratio commonly known as the PEG ratio implies the stock’s valuation compared to earnings growth potential. Investors look to invest in the stocks with a lower PEG ratio. For Impax Laboratories, Inc., the PEG ratio for coming 3-5 years is 0.60.
The technical analysis highlights that Impax Laboratories, Inc. current is trading $-6.26 points away or -21.42% from its 50-day moving average of $29.21. Further it is trading $-9.19 or -28.58% away its 200-day moving average of $32.14.
The 52-week high of Impax Laboratories, Inc. (NASDAQ:IPXL) was $47.48 while lowest point recorded in 52-week was $20.97. It implies if stock price makes a movement of over $-24.53, it will record a new 52-week high. In the case of +9.44% drop, it will touch a new 52-week low.
1 Chart Pattern Every Investor Should Know